

Synthesis of Ethyl 5-*O*-(α -D-arabinofuranosyl)-6-*O*- (β -D-galactofuranosyl)- β -D-galactofuranoside Present in Motif E of the *Mycobacterium tuberculosis* Cell Wall


Mukund K. Gurjar,* L. Krishnakanth Reddy, and Srinivas Hotha

National Chemical Laboratory, Pune 411 008, India

gurjar@dalton.ncl.res.in

Received October 3, 2000

ABSTRACT



The stereocontrolled synthesis of the trisaccharide ethyl 5-*O*-(α -D-arabinofuranosyl)-6-*O*-(β -D-galactofuranosyl)- β -D-galactofuranoside present in motif E of the *Mycobacterium tuberculosis* cell wall is described.

Three million deaths occur every year due to tuberculosis, and perhaps it constitutes the single largest lethal disease of the world.¹ The mycobacterium species, namely *Mycobacterium tuberculosis* and *M. avium* and to lesser extent *M. kansasii*, are associated with AIDS, and therefore, in recent years, they have attracted unprecedented attention. The impact of tuberculosis, as an opportunistic infection, on developing countries has been phenomenal because of increasing incidences of AIDS in these countries.^{2–4}

The unique cell wall structure of *M. tuberculosis* contains two major polysaccharides, lipoarabinomannan (LAM) and arabinogalactan (AG), in which both arabinose and galactose residues are found in the furanose form.⁵

The five major motifs of AG, namely motifs A–E (1–5), have been isolated and characterized⁶ as shown in Figure 1. Synthesis of these motifs provides opportunities to investigate, in detail, their role in immunological response arising from mycobacterial infection. The structural analysis revealed that motifs A,^{7a,8a} B, and C^{8c} contain only arabinofuranose residues, whereas motif D has exclusively galactofuranoses. Motif E is novel and unique because of the presence of the both arabinofuranose and galactofuranose residues in its structural framework. In addition, the oligosaccharide structure of motif E is sterically complicated because both the 5- and 6- positions of the reducing

(5) McNeil, M.; Wallner, S. J.; Hunter, S. W.; Brennan, P. J. *Carbohydr. Res.* **1987**, *166*, 299.

(6) (a) Besra, G. S.; Khoo, K.-H.; McNeil, M. R.; Dell, A.; Morris, H. R.; Brennan, P. J. *Biochemistry* **1995**, *34*, 4257. (b) Wolucka, B. A.; McNeil, M. R.; de Hoffmann, E.; Chojnacki, T.; Brennan, P. J. *J. Biol. Chem.* **1994**, *269*, 23328. (c) McNeil, M. R.; Daffe, M.; Brennan, P. J. *J. Biol. Chem.* **1990**, *265*, 18200. (d) Daffe, M.; Brennan, P. J.; McNeil, M. J. *Biol. Chem.* **1990**, *265*, 6734. (e) Lee, R. E.; Mikušová, K.; Brennan, P. J.; Besra, G. S. *J. Am. Chem. Soc.* **1995**, *117*, 11829.

(1) Lee, R. E.; Brennan, P. J.; Besra, G. S. Tuberculosis. In *Current Topics in Microbiology and Immunology*; Shinnick, T. M., Ed.; Springer-Verlag: Berlin, 1996; Chapter 1, p 215.

(2) Spinney, L. *New Sci.* **1996**, *8*.

(3) Gilbert, G. L. *Med. J. Aust.* **1996**, *154*, 121.

(4) Valainis, G. T.; Cardona, I. M.; Greer, D. L. *JAIDS, J. Acquired Immune Defic. Syndr.* **1991**, *4*, 516.





Figure 1.


galactofuranose component are linked with arabinofuranosyl and galactofuranosyl residues, respectively. The synthesis of the pentaarabinofuranoside of motif A (1) was first described from our laboratories. This communication reports the first stereocontrolled synthesis of 5-*O*-(α -D-arabinofuranosyl)-6-*O*-(β -D-galactofuranosyl)- β -D-galactofuranose as ethyl glycoside **6** (Figure 1) belonging to motif E.

Our first concern was the preparation of the aglycone (**8**) in which the 2- and 3-positions are blocked with permanent protecting benzyl ethers while the 6-position is blocked with a temporary protecting TBDPS ether. The known ethyl 2,3-di-*O*-benzyl- β -D-galactofuranose **7**,⁹ obtained from D-galactose in 5 steps, was treated with TBDPS-chloride in the presence of imidazole to give the 6-*O*-TBDPS derivative **8** (Scheme 1).




2,3,5-Tri-*O*-acetyl-D-arabinofuranosyl trichloroimidate (**11**), as the glycosylating agent, was obtained by selective deprotection of the 1-*O*-acetyl group of 1,2,3,5-tetra-*O*-

acetyl- α -D-arabinofuranose (**9**)¹⁰ with tri-*n*-butyltin ethoxide in refluxing ClCH₂CH₂Cl and subsequent exposure of **10** with CCl₃CN–DBU–CH₂Cl₂ at 0 °C (Scheme 2).



A coupling reaction¹¹ between **8** and **11** was carried out, with BF₃·OEt₂ as an activator, to give the disaccharide **12** which was isolated in 70% yield and characterized after Zemplén deacetylation¹² (Scheme 3). The ¹H NMR and ¹³C




NMR spectra of **13** were in complete agreement with the assigned structure.¹³ The location of the signal due to C-1' at δ 104.5 in the ¹³C NMR spectrum of **13** confirmed the α -linkage at the newly formed glycosidic bond.¹³ Compound **13** was transformed into the 2,2',3,3',5',5'-penta-*O*-benzyl

(7) (a) Gurjar, M. K.; Hotha, S.; Mereyala, H. B. *J. Chem. Soc., Chem. Comm.* **1998**, 685. Other interesting reports on mycobacteria: (b) Gurjar, M. K.; Adhikari, S. *Tetrahedron* **1997**, *53*, 8629. (c) Gurjar, M. K.; Reddy, K. R. *J. Chem. Soc., Perkin Trans 1* **1993**, 1265. (d) Gurjar, M. K.; Saha, U. K. *Bioorg. Med. Chem. Lett.* **1993**, *3*, 697. (e) Gurjar, M. K.; Mainkar, P. S. *Carbohydr. Res.* **1993**, *239*, 297. (f) Gurjar, M. K.; Saha, U. K. *Tetrahedron Lett.* **1992**, *33*, 4979. (g) Gurjar, M. K.; Mainkar, A. S. *Tetrahedron* **1992**, *48*, 6729. (h) Gurjar, M. K.; Saha, U. K. *Tetrahedron* **1992**, *48*, 4039. (i) Gurjar, M. K.; Reddy, K. R. *Carbohydr. Res.* **1992**, *226*, 232. (j) Gurjar, M. K.; Viswanadham, G. *Tetrahedron Lett.* **1991**, *32*, 6191. (k) Gurjar, M. K.; Viswanadham, G. *J. Carbohydr. Chem.* **1991**, *10*, 481.

(8) (a) D'Souza, F. W.; Lowary, T. L. *Org. Lett.* **2000**, *2*, 1493. (b) D'Souza, F. W.; Ayers, J. D.; McCarren, P. R.; Lowary, T. L. *J. Am. Chem. Soc.* **2000**, *122*, 1251. (c) Ayers, A. D.; Lowary, T. L.; Morehouse, C. B.; Besra, G. S. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 437.


derivative (**14**) by using NaH and benzyl bromide in DMF. Removal of the temporary TBDPS protecting group with 1 M Bu₄NF solution in THF gave the aglycone (**15**) containing the 6-hydroxyl (Scheme 3).

The glycosidation reaction of **15**, with substituted galactofuranosyl derivatives, turned out to be a difficult proposition because trichloroacetimidate methodology,¹¹ SET promoted glycosidation,¹⁴ and Helfrich reaction¹⁴ failed in our hands. Finally, Fraser-Ried's *n*-pentenyl glycosidation technique¹⁵ was successful. Thus, 1,2,3,5,6-penta-*O*-acetyl-β-D-galactofuranose **16**¹⁶ and 4-penten-1-ol in the presence of a catalytic amount of BF₃·OEt₂ in CH₂Cl₂ at 0 °C gave the β-pentenyl glycoside derivative **17** (Scheme 4).



The coupling reaction between **15** and **17** in the presence of *N*-iodosuccinamide and triflic acid (cat.) in CH₂Cl₂ at ambient temperature for 48 h gave the trisaccharide **18**. The Zemplen deacetylation of **18** provided the penta-*O*-benzylated derivative **19** which was analyzed by the ¹H NMR and ¹³C NMR spectral data. For example, in the ¹H NMR spectrum of **19**, signals due to three anomeric protons were observed at δ 4.85, 4.95, and 5.17 as singlets. The ¹³C NMR spectrum showed anomeric carbons at δ 105.3, 107.0, and

107.8. Finally, compound **19** was deprotected by hydrolysis over 10% Pd(OH)₂/C in methanol to give the target molecule **6** (Scheme 5).



(a) NIS, TfOH (Cat.), CH₂Cl₂, 4 Å MS powder, rt, 48 h, 65 %; (b) NaOMe, MeOH, rt, 2 h, 72 %; (c) 10% Pd(OH)₂/C, MeOH, H₂, rt, 8 h, 90%.

The high resolution ¹H NMR spectrum of **6** showed resonances due to anomeric protons at δ 4.89, 4.93, and 5.10 as singlets. The chemical shifts of anomeric carbons were revealed at δ 106.5, 107.5, and 108.2 in the ¹³C NMR spectrum. In addition, the FAB-MS and elemental analysis of **6** were in complete agreement with the assigned structure.

In conclusion, this communication reports the first synthesis of a novel trisaccharide present in motif E of *Mycobacterium tuberculosis*. The arabinogalactan caused profound interest for two fundamental reasons, (1) it appears to be essential for viability and (2) three out of the four sugars, namely *araf*, *galf*, and *rhamp*, are not found in humans. Only recently it has been established that ethambutol, the drug of choice for TB since 35 years, is involved in the inhibition of biosynthetic pathway of arabinan, thus establishing it to be a valuable target for the discovery of new drugs.^{6e,17}

Acknowledgment. L.K.R. and S.H. thank CSIR (New Delhi) for financial assistance in the form of a Senior Research Fellowship.

Supporting Information Available: ¹H and ¹³C NMR spectra of **6**, **13**, **14**, and **19**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL0002976

(17) (a) Deng, L.; Mikušová, K.; Robuck, K. G.; Scherman, M.; Brennan, P. J.; McNeil, M. R. *Antimicrob. Agents Chemother.* **1995**, *39*, 694.

- (9) Thiem, J.; Wessel, H.-P. *Tetrahedron Lett.* **1980**, *21*, 3571.
 (10) Kam, B. L.; Barascut, J.-L. Imbach, J.-L. *Carbohydr. Res.* **1979**, *69*, 135.
 (11) (a) Schmidt, R. R.; Michel, J. *Angew. Chem., Int. Ed. Engl.* **1980**, *19*, 731. (b) Schmidt, R. R. *Angew. Chem., Int. Ed. Engl.* **1986**, *25*, 212.
 (12) McAuliffe, J. C.; Hinds Gaul, O. *J. Org. Chem.* **1997**, *62*, 1234.
 (13) Mizutani, K.; Kasai, R.; Nakamura, M.; Tanaka, O.; Matsuura, H. *Carbohydr. Res.* **1989**, *185*, 27.
 (14) Toshima, K.; Tatsuta, K. *Chem. Rev.* **1993**, *93*, 1503.
 (15) (a) Mootoo, D. R.; Konradsson, P.; Udodong, U.; Fraser-Ried, B. *J. Am. Chem. Soc.* **1988**, *110*, 5583. (b) Konradsson, P.; Mootoo, D. R.; McDevitt, R. E.; Fraser-Reid, B. *J. Chem. Soc., Chem. Commun.* **1990**, 270. (c) Fraser-Reid, B.; Udodong, U. E.; Wu, Z.; Ottosson, H.; Merritt, J. R.; Rao, C. S.; Roberts, C.; Madsen, R. *Synlett.* **1992**, 927.
 (16) Chittenden, G. J. F.; *Carbohydr. Res.* **1972**, *25*, 35.